Click here for Bosulif®▼ (bosutinib monohydrate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Bosulif has been authorised under a conditional approval scheme. Since Bosulif has been granted a conditional approval, the company that markets Bosulif will carry out and submit the results of a larger study with Bosulif in patients with Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors (TKIs) and for whom dasatinib, imatinib and nilotinib are not considered appropriate treatment options.1
BOSULIF is indicated for the treatment of adult patients with2:
Watch Prof. Richard Clark discuss the holistic approach to treatment decisions for patient with CML
Understand the data for Bosulif in 2nd line and beyond
Hear Dr. Alex Lyon’s views on long-term TKI treatment in an ageing patient population video
Learn more on new challenges in CML
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020